Transgenic Inc.

Tokyo Metropolitan Government

Tokyo Metropolitan Organization for Medical Research

Crc Inc.

Tokyo Metropolitan Institute of Medical Science

Kyoko Hiramatsu

Masao Kawakita

Naotaka Hamasaki

Koji Yamaguchi

Seiji Naito

Shingo Shinagawa

Chiemi Minoda

Mika Ito

Yosuke Mizukami

Yusei Nagase

Masato Kato

Toru Inoue

Shoshu Mitsuyama

Jun Hayashi

Munechika Enjoji

Koichiro Muta

Tsunehisa Kaku

Keiichi Takahashi

Hiroyuki Yamashita

Jun c/o Kyushu University Hayashi

Hiroyuki c/o Noguchi Thyroid Clinic Yamashita

Seiji c/o Kyushu University Naito

Masato c/o Hamanomachi Hospital Kato

Tohru c/o National Kyushu Medical Center Inoue

Tsunehisa c/o Kyushu University Kaku

Kouichiro c/o Kyushu University Muta

Kouji Yamaguchi

Shoshu Kitakyushu Municipal Medica Ctr Mitsuyama

Munechika c/o Kyushu University Enjoji

A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.

Method of detecting colorectal cancer of stages 0 to I

The present invention provides an anti-diacetylspermine specific monoclonal antibody which satisfies a specific measuring condition in an immunoreaction system between a solid-phased diacetylspermine and the anti-diacetylspermine specific monoclonal antibody, wherein the immunoreaction system comprises a sample diacetylspermine or sample N-acetylspermidine to inhibit the immunoreaction; and the specific measuring condition is that the 50% inhibition activity against the immunoreaction by the diacetylspermine in the sample is at least 1,000 times as much as the 50% inhibition activity against the immunoreaction by the N-acetylspermidine in the sample.

[object Object]

Growing community of inventors

Tokyo, Japan

Kyoko Hiramatsu